Caroline A Arout1,2, Andrew J Waters3, R Ross MacLean4,5, Peggy Compton6, Mehmet Sofuoglu4,5. 1. Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA. Caroline.Arout@nyspi.columbia.edu. 2. Department of Psychiatry, New York State Psychiatric Institute, Columbia University Irving Medical Center, 1051 Riverside Drive, Unit 120, New York, NY, 10032, USA. Caroline.Arout@nyspi.columbia.edu. 3. Department of Medical and Clinical Psychology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA. 4. Department of Psychiatry, Yale University School of Medicine, West Haven, CT, USA. 5. Veterans Health Administration Mental Illness Research, Education, and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA. 6. Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, PA, USA.
Abstract
RATIONALE: Minocycline, a tetracycline antibiotic, inhibits activation of microglia. In preclinical studies, minocycline prevented development of opioid tolerance and opioid-induced hyperalgesia (OIH). The goal of this study was to determine if minocycline changes pain threshold and tolerance in individuals with opioid use disorder who are maintained on agonist treatment. METHODS: In this double-blind, randomized human laboratory study, 20 participants were randomized to either minocycline (200 mg/day) or placebo treatment for 15 days. The study had three test sessions (days 1, 8, and 15 of treatment) and one follow-up visit 1 week after the end of treatment. In each test session, participants were assessed on several subjective and cognitive measures, followed by assessment of pain sensitivity using the Cold Pressor Test (CPT). Daily surveys and cognitive measures using Ecological Momentary Assessment (EMA) were also collected four times a day on days 8 through 14 of treatment, and proinflammatory serum cytokines were assessed before and on the last day of treatment. RESULTS:Minocycline treatment did not change pain threshold or tolerance on the CPT. Similarly, minocycline did not change severity of pain, opioid craving, withdrawal, or serum cytokines. Minocycline treatment increased accuracy on a Go/No-Go task. CONCLUSIONS: While these findings do not support minocycline's effects on OIH, minocycline may have a potential use as a cognitive enhancer for individuals with opioid use disorder, a finding that warrants further systematic studies.
RCT Entities:
RATIONALE: Minocycline, a tetracycline antibiotic, inhibits activation of microglia. In preclinical studies, minocycline prevented development of opioid tolerance and opioid-induced hyperalgesia (OIH). The goal of this study was to determine if minocycline changes pain threshold and tolerance in individuals with opioid use disorder who are maintained on agonist treatment. METHODS: In this double-blind, randomized human laboratory study, 20 participants were randomized to either minocycline (200 mg/day) or placebo treatment for 15 days. The study had three test sessions (days 1, 8, and 15 of treatment) and one follow-up visit 1 week after the end of treatment. In each test session, participants were assessed on several subjective and cognitive measures, followed by assessment of pain sensitivity using the Cold Pressor Test (CPT). Daily surveys and cognitive measures using Ecological Momentary Assessment (EMA) were also collected four times a day on days 8 through 14 of treatment, and proinflammatory serum cytokines were assessed before and on the last day of treatment. RESULTS:Minocycline treatment did not change pain threshold or tolerance on the CPT. Similarly, minocycline did not change severity of pain, opioid craving, withdrawal, or serum cytokines. Minocycline treatment increased accuracy on a Go/No-Go task. CONCLUSIONS: While these findings do not support minocycline's effects on OIH, minocycline may have a potential use as a cognitive enhancer for individuals with opioid use disorder, a finding that warrants further systematic studies.
Authors: Mehmet Sofuoglu; Marc Mooney; Thomas Kosten; Andrew Waters; Kenji Hashimoto Journal: Psychopharmacology (Berl) Date: 2010-09-14 Impact factor: 4.530
Authors: Marc O Martel; Patrick H Finan; R Kathryn McHugh; Mohammed Issa; Robert R Edwards; Robert N Jamison; Ajay D Wasan Journal: Drug Alcohol Depend Date: 2016-03-18 Impact factor: 4.492
Authors: Ismene L Petrakis; Elizabeth Ralevski; Ralitza Gueorguieva; Matthew E Sloan; Lesley Devine; Gihyun Yoon; Albert J Arias; Mehmet Sofuoglu Journal: Psychopharmacology (Berl) Date: 2019-03-27 Impact factor: 4.530